Stanley Druckenmiller is closely associated with Duquesne Family Office.
Duquesne Family Office LLC Holdings · Q1 2026
Estimated gain compares the quarter-end mark with a running share-weighted mean of covered-snapshot and add-quarter mean prices. Holdings with incomplete basis or price coverage are excluded.
| Stock | % | Avg. buy price | Estimated gain | Quarter-end price | Last transaction | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Avg. buy price
$45.28
Estimated gain+158.5%Quarter-end price
$117.07
Last transaction
New· Q3 2025Opened a new position
|
|
0.2% | $45.28 | +158.5% | $117.07 | New· Q3 2025Opened a new position | |||||
|
Avg. buy price
$78.34
Estimated gain+108.7%Quarter-end price
$163.52
Last transaction
Reduced· Q1 2026Sold 22.1% of shares
|
|
6.4% | $78.34 | +108.7% | $163.52 | Reduced· Q1 2026Sold 22.1% of shares | |||||
|
Avg. buy price
$9.90
Estimated gain+97.4%Quarter-end price
$19.55
Last transaction
Reduced· Q1 2026Sold 34.0% of shares
|
|
0.4% | $9.90 | +97.4% | $19.55 | Reduced· Q1 2026Sold 34.0% of shares | |||||
|
Avg. buy price
$111.63
Estimated gain+79.1%Quarter-end price
$199.99
Last transaction
Added· Q1 2026Increased shares by 22.0%
|
|
20.9% | $111.63 | +79.1% | $199.99 | Added· Q1 2026Increased shares by 22.0% | |||||
|
Avg. buy price
$190.50
Estimated gain+77.4%Quarter-end price
$337.95
Last transaction
Reduced· Q1 2026Sold 8.8% of shares
|
|
5.7% | $190.50 | +77.4% | $337.95 | Reduced· Q1 2026Sold 8.8% of shares | |||||
|
Avg. buy price
$17.86
Estimated gain+68.7%Quarter-end price
$30.12
Last transaction
Reduced· Q1 2026Sold 59.5% of shares
|
|
2.4% | $17.86 | +68.7% | $30.12 | Reduced· Q1 2026Sold 59.5% of shares | |||||
|
Avg. buy price
$42.52
Estimated gain+56.0%Quarter-end price
$66.33
Last transaction
Added· Q1 2026Increased shares by 8.5%
|
|
3.4% | $42.52 | +56.0% | $66.33 | Added· Q1 2026Increased shares by 8.5% | |||||
|
Avg. buy price
$177.17
Estimated gain+41.1%Quarter-end price
$249.91
Last transaction
Reduced· Q1 2026Sold 68.4% of shares
|
|
0.8% | $177.17 | +41.1% | $249.91 | Reduced· Q1 2026Sold 68.4% of shares | |||||
|
Avg. buy price
$59.30
Estimated gain+35.9%Quarter-end price
$80.57
Last transaction
New· Q1 2026Opened a new position
|
|
0.4% | $59.30 | +35.9% | $80.57 | New· Q1 2026Opened a new position | |||||
|
Avg. buy price
$71.19
Estimated gain+30.3%Quarter-end price
$92.76
Last transaction
Reduced· Q1 2026Sold 65.1% of shares
|
|
1.0% | $71.19 | +30.3% | $92.76 | Reduced· Q1 2026Sold 65.1% of shares | |||||
|
Avg. buy price
$105.09
Estimated gain+28.9%Quarter-end price
$135.49
Last transaction
Reduced· Q1 2026Sold 81.6% of shares
|
|
0.6% | $105.09 | +28.9% | $135.49 | Reduced· Q1 2026Sold 81.6% of shares | |||||
|
Avg. buy price
$551.10
Estimated gain+27.5%Quarter-end price
$702.76
Last transaction
New· Q1 2026Opened a new position
|
|
0.2% | $551.10 | +27.5% | $702.76 | New· Q1 2026Opened a new position | |||||
|
Avg. buy price
$135.75
Estimated gain+26.7%Quarter-end price
$172.06
Last transaction
Added· Q1 2026Increased shares by 0.8%
|
|
0.7% | $135.75 | +26.7% | $172.06 | Added· Q1 2026Increased shares by 0.8% | |||||
|
Avg. buy price
$121.40
Estimated gain+24.6%Quarter-end price
$151.28
Last transaction
New· Q1 2026Opened a new position
|
|
0.5% | $121.40 | +24.6% | $151.28 | New· Q1 2026Opened a new position | |||||
|
Avg. buy price
$96.97
Estimated gain+20.5%Quarter-end price
$116.82
Last transaction
New· Q1 2026Opened a new position
|
|
0.1% | $96.97 | +20.5% | $116.82 | New· Q1 2026Opened a new position | |||||
A
Amazon.com, Inc. (AMZN)
−$153M
G
Alphabet Inc. (GOOGL)
Exited−$121M
T
Teva Pharmaceutical Industries Limited (TEVA)
−$113M
E
Entegris, Inc. (ENTG)
Exited−$100M
B
Bloom Energy Corporation (BE)
−$89M
M
MercadoLibre, Inc. (MELI)
−$86M
C
Cogent Biosciences, Inc. (COGT)
Exited−$82M
C
Coupang, Inc. (CPNG)
−$80M
N
Natera, Inc. (NTRA)
+$119M
A
Broadcom Inc. (AVGO)
New+$64M
C
Caris Life Sciences, Inc. (CAI)
New+$41M
R
Revolution Medicines, Inc. (RVMD)
New+$32M
H
Humana Inc. (HUM)
New+$28M
N
Nuvation Bio Inc. (NUVB)
New+$25M
T
Twilio Inc. (TWLO)
New+$22M
S
Sandisk Corporation (SNDK)
New+$22M
W
Woodward, Inc. (WWD)
−380K
W
Wolfspeed Inc. (WOLF)
Exited−187K
C
Cidara Therapeutics, Inc. (CDTX)
Exited−49K
Y
YPF Sociedad Anónima (YPF)
+2.6M
S
STMicroelectronics N.V. (STM)
+1.8M
O
Olema Pharmaceuticals, Inc. (OLMA)
New+987K
T
BBB Foods Inc. (TBBB)
+434KLargest holdings in Q1 2026, sized by their share of the disclosed portfolio. This shows what is owned, not what changed.
Stanley Druckenmiller is closely associated with Duquesne Family Office. This page shows Duquesne's quarterly Form 13F report of certain United States listed long positions, not Druckenmiller's personal account or the family office's complete portfolio. Cash, short positions, private assets, many derivatives, and some foreign securities may be absent.
Profile refreshed July 20, 2026
As of the Q1 2026 filing, Stanley Druckenmiller's largest disclosed holdings are Natera, Inc. (NTRA), Insmed Incorporated (INSM), Taiwan Semiconductor Manufacturing Company Limited (TSM). The table shows 15 of 65 positions by default, with an exact-count control for the remaining rows. Disclosed shares and values remain visible even when a separate market-price estimate is unavailable.
The biggest disclosed buys in Q1 2026 were Natera, Inc. (NTRA), Broadcom Inc. (AVGO), Caris Life Sciences, Inc. (CAI), based on the Duquesne Family Office LLC 13F filing. New positions are marked "new" in the table above.
The biggest reductions in Q1 2026 were Amazon.com, Inc. (AMZN), Teva Pharmaceutical Industries Limited (TEVA), Bloom Energy Corporation (BE). The filing comparison contains 19 full exits, summarized in the activity view above.
The latest 13F discloses $2.9B across 65 positions in Q1 2026. 13F filings cover US-listed long positions only; cash and short positions are not disclosed.
Funds file 13Fs up to 45 days after each quarter ends, so this portfolio reflects Q1 2026, the latest disclosed quarter. The filing date is shown with every table.
Non-rejected, non-superseded SEC Form 13F filings for Duquesne Family Office LLC provide the Q1 2026 holdings, disclosed values, and filing date shown here. WhoBought prefers filings whose value units validate and labels a sparse filing when validation is unavailable. Industry labels come from the local company classification record.
Performance uses daily closing prices for holdings with available market-price history. It covers the priced share of disclosed value (67%); holdings without sufficient price history are excluded from the calculation.
Stanley Druckenmiller is an American investor who founded Duquesne Capital in 1981 and later became the lead portfolio manager for George Soros's Quantum Fund.
After studying English and economics at Bowdoin, he left an economics PhD program to become an oil analyst at Pittsburgh National Bank. He founded Duquesne a few years later.
Druckenmiller and George Soros took a large short position against the British pound in 1992 after concluding that the Bank of England could not sustain its defense of the currency.
No. He returned outside investors' money and closed Duquesne Capital in 2010. This page instead follows the later Duquesne Family Office filing.
Wikipedia reports an average annual return of about 30 percent with no money-losing year during the fund's run. That historical figure is separate from the current family-office holdings shown here.
He is a top-down investor who has combined long and short stock positions with leverage, futures, and currency trades. That makes a stock-only 13F an incomplete picture of his approach.
No. It is the Duquesne Family Office 13F filing. It does not calculate his personal wealth or disclose every asset held by the family office.
No. The filing can reveal selected long equity positions, but it leaves out the shorts, currencies, futures, leverage, and timing decisions central to his style.